VEGFA and duodenal adenocarcinoma: In addition, several patients with tumor types not known to benefit from anti-VEGF therapy (duodenal adenocarcinoma, squamous cell carcinoma of the cervix, and cholangiocarcinoma) had stable disease for at least 6 months.